Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Jessica Jensen
Eli Lilly and Company
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
54 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Bc Cancer - Vancouver
Vancouver, British Columbia, Canada
- Nova Scotia Health Authority
Halifax, Nova Scotia, Canada
- London Health Sciences Center - Victoria Hospital
London, Ontario, Canada
- Princess Margaret Cancer Centre
Toronto, Ontario, Canada
- Sunnybrook Research Institute, Odette Cancer Center
Toronto, Ontario, Canada
- Chum - University Hospital of Montreal
Montreal, Quebec, Canada
- Jewish General Hospital
Montreal, Quebec, Canada
- Chu of Quebec - Laval University
Québec, Quebec, Canada
- Center Jean Perrin, Department of Medical Oncology
Clermont-Ferrand, France
- Claude Huriez Hospital
Lille, France
- Leon Berard Center
Lyon, France
- la Timone Hospital, Nuclear Medicine Department
Marseille, France
- Montpellier Cancer Institute, Department of Nuclear Medicine
Montpellier, France
- Tenon Hospital, Department of Medical Oncology
Paris, France
- St. Antonius Hospital
Nieuwegein, Netherlands
- Radboud University Medical Center (radboudumc)
Nijmegen, Netherlands
- Erasmus University Medical Center Rotterdam
Rotterdam, Netherlands
- Sahlgrenska University Hospital
Gothenburg, Sweden
- Norrlands University Hospital, Department of Radiation Sciences, Oncology
Umeå, Sweden
- Charing Cross Hospital, Department of Medical Oncology
London, United Kingdom
- Royal Marsden Nhs Foundation Trust - Institute of Cancer Research
Sutton, United Kingdom
- Arizona Institute of Urology (aiu) - Tucson
Tucson, Arizona, United States
- Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute
Los Angeles, California, United States
- University of California Los Angeles, Nuclear Medicine Clinic
Los Angeles, California, United States
- Va Greater Los Angeles Healthcare System
Los Angeles, California, United States
- Hoag Memorial Hospital Presbyterian
Newport Beach, California, United States
- Uc Irvine Chao Family Comprehensive Cancer Center
Orange, California, United States
- Stanford Cancer Institute
Palo Alto, California, United States
- University of Colorado Hospital
Aurora, Colorado, United States
- H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States
- University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
- University of Kentucky Chandler Medical Center
Lexington, Kentucky, United States
- Tulane University Medical Center
New Orleans, Louisiana, United States
- University of Maryland Greenebaum Cancer Center
Baltimore, Maryland, United States
- Chesapeake Urology Associates (cua) P.A.
Towson, Maryland, United States
- University of Michigan Hospitals
Ann Arbor, Michigan, United States
- Karmanos Cancer Center
Detroit, Michigan, United States
- Saint Louis University Hospital
St Louis, Missouri, United States
- Va St. Louis Health Care System
St Louis, Missouri, United States
- Washington University School of Medicine
St Louis, Missouri, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 25 Feb 2021
- Primary completion
- 1 Nov 2023
- Completion
- 31 Mar 2028
- Last update posted
- 13 Jan 2026
- Registered enrollment
- 455
- Registry id
- NCT04647526
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.